Argos Therapeutics (NASDAQ: ARGS) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Institutional and Insider Ownership

29.2% of Argos Therapeutics shares are held by institutional investors. Comparatively, 6.9% of Kamada shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Argos Therapeutics and Kamada’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Argos Therapeutics $950,000.00 18.50 -$53.02 million ($1.12) -0.18
Kamada $77.49 million 2.42 -$6.73 million ($0.18) -25.83

Kamada has higher revenue and earnings than Argos Therapeutics. Kamada is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Argos Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Argos Therapeutics and Kamada, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 3 0 0 2.00
Kamada 0 0 2 0 3.00

Argos Therapeutics presently has a consensus target price of $4.13, indicating a potential upside of 1,966.67%. Kamada has a consensus target price of $8.50, indicating a potential upside of 82.80%. Given Argos Therapeutics’ higher possible upside, analysts plainly believe Argos Therapeutics is more favorable than Kamada.

Profitability

This table compares Argos Therapeutics and Kamada’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -13,750.64% -1,532.49% -120.95%
Kamada -1.27% -1.64% -1.14%

Summary

Kamada beats Argos Therapeutics on 8 of the 13 factors compared between the two stocks.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.